We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+6.82%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.27B
AUM Growth
+$432M
Cap. Flow
+$259M
Cap. Flow %
7.92%
Top 10 Hldgs %
37.03%
Holding
113
New
28
Increased
27
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$111M
2
MYGN icon
Myriad Genetics
MYGN
+$77.2M
3
BAX icon
Baxter International
BAX
+$36.4M
4
BFLY icon
Butterfly Network
BFLY
+$36.2M
5
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$35.7M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$52.7M
2
IRTC icon
iRhythm Holdings
IRTC
+$40.6M
3
PEN icon
Penumbra
PEN
+$32.4M
4
BMY icon
Bristol-Myers Squibb
BMY
+$28M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$27.6M

Sector Composition

Rank Sector Weight
1 Healthcare 81.98%
2 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
101
Revolution Medicines
RVMD
$42.1B
– –
-209,116
Closed -$8.28M
XLF icon
102
CALL
State Street Financial Select Sector SPDR ETF
XLF
$58.4B
– –
-1,188,100
Closed -$35M
MRTX
103
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-44,300
Closed -$9.73M
TCRR
104
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-775,794
Closed -$24M
MYOV
105
CALL
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-411,500
Closed -$11.4M
TRIL
106
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-599,111
Closed -$8.81M
ALXN
107
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-300,000
Closed -$46.9M
HZNP
108
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-217,900
Closed -$15.9M
1 2 3 4
5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
PWA
Pitcairn Wealth Advisors Conshohocken, Pennsylvania $1.09B AUM

PFM Health Sciences's Q1 2021 Portfolio in Review

As of Q1 2021, PFM Health Sciences held 113 positions worth $3.27B, up 15% from $2.84B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

PFM Health Sciences deployed $259M of net new capital in Q1 2021, opening 28 new positions and adding to 27 existing holdings. Its largest new stake was Neurocrine Biosciences: 1,055,510 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Penumbra, an estimated $32.4M trimmed.

  • PFM Health Sciences's largest Q1 2021 buy was Neurocrine Biosciences: 1,055,510 shares worth $103M.
  • PFM Health Sciences added most to Eli Lilly in Q1 2021, an estimated $34.2M increase.
  • PFM Health Sciences's biggest Q1 2021 reduction was Penumbra, cutting an estimated $32.4M.
  • PFM Health Sciences fully exited Elevance Health in Q1 2021, selling an estimated $52.7M.
  • PFM Health Sciences's ten largest holdings make up 37% of its $3.27B portfolio in Q1 2021.
  • PFM Health Sciences opened 28 new positions and closed 27 in Q1 2021.
  • PFM Health Sciences's portfolio value rose 15% quarter-over-quarter to $3.27B.

Based on PFM Health Sciences's 13F filing for Q1 2021, filed 17 May 2021.